volume 19 issue 9 pages 758-766

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches

Publication typeJournal Article
Publication date2020-09-01
scimago Q1
wos Q1
SJR11.729
CiteScore62.6
Impact factor45.5
ISSN14744422, 14744465
Neurology (clinical)
Abstract
Insulin is a peptide secreted by the pancreas and plays an important role in the regulation of glucose metabolism in peripheral tissues. Although the role of insulin in the periphery is well understood, less is known about its multifactorial role in the brain. However, emerging evidence from human and animal studies indicate that insulin influences cerebral bioenergetics, enhances synaptic viability and dendritic spine formation, and increases turnover of neurotransmitters, such as dopamine. Insulin also has a role in proteostasis, influencing clearance of the amyloid β peptide and phosphorylation of tau, which are hallmarks of Alzheimer's disease. Insulin also modulates vascular function through effects on vasoreactivity, lipid metabolism, and inflammation. Through these multiple pathways, insulin dysregulation could contribute to neurodegeneration. Thus, new approaches to restore cerebral insulin function that could offer therapeutic benefit to adults with Alzheimer's disease, vascular cognitive impairment, or related disorders are being investigated.
Found 
Found 

Top-30

Journals

5
10
15
20
25
30
International Journal of Molecular Sciences
26 publications, 4.04%
Journal of Alzheimer's Disease
26 publications, 4.04%
Frontiers in Aging Neuroscience
13 publications, 2.02%
Frontiers in Endocrinology
13 publications, 2.02%
Alzheimer's and Dementia
13 publications, 2.02%
Ageing Research Reviews
12 publications, 1.87%
Frontiers in Neuroscience
10 publications, 1.56%
Frontiers in Pharmacology
9 publications, 1.4%
Nutrients
9 publications, 1.4%
CNS Neuroscience and Therapeutics
8 publications, 1.24%
Molecular Neurobiology
8 publications, 1.24%
Biomedicine and Pharmacotherapy
7 publications, 1.09%
Alzheimer's Research and Therapy
6 publications, 0.93%
Scientific Reports
5 publications, 0.78%
Metabolic Brain Disease
5 publications, 0.78%
Life Sciences
5 publications, 0.78%
Neuroscience and Biobehavioral Reviews
5 publications, 0.78%
Biology
4 publications, 0.62%
Biomedicines
4 publications, 0.62%
Cells
4 publications, 0.62%
GeroScience
4 publications, 0.62%
Journal of Affective Disorders
4 publications, 0.62%
Neurobiology of Disease
4 publications, 0.62%
PLoS ONE
4 publications, 0.62%
Journal of Neuroendocrinology
4 publications, 0.62%
Diabetes Care
4 publications, 0.62%
Frontiers in Nutrition
4 publications, 0.62%
Frontiers in Public Health
3 publications, 0.47%
Pharmaceuticals
3 publications, 0.47%
5
10
15
20
25
30

Publishers

20
40
60
80
100
120
140
160
Elsevier
150 publications, 23.33%
Springer Nature
129 publications, 20.06%
Frontiers Media S.A.
71 publications, 11.04%
MDPI
66 publications, 10.26%
Wiley
58 publications, 9.02%
Cold Spring Harbor Laboratory
25 publications, 3.89%
SAGE
24 publications, 3.73%
Taylor & Francis
16 publications, 2.49%
Ovid Technologies (Wolters Kluwer Health)
8 publications, 1.24%
Bentham Science Publishers Ltd.
6 publications, 0.93%
American Chemical Society (ACS)
6 publications, 0.93%
Oxford University Press
6 publications, 0.93%
IOS Press
5 publications, 0.78%
American Diabetes Association
5 publications, 0.78%
Georg Thieme Verlag KG
5 publications, 0.78%
Public Library of Science (PLoS)
4 publications, 0.62%
Spandidos Publications
3 publications, 0.47%
SciELO
3 publications, 0.47%
Hindawi Limited
3 publications, 0.47%
American Physiological Society
3 publications, 0.47%
American Society for Biochemistry and Molecular Biology
2 publications, 0.31%
Aging and Disease
2 publications, 0.31%
BMJ
2 publications, 0.31%
Walter de Gruyter
2 publications, 0.31%
The Endocrine Society
2 publications, 0.31%
Research Square Platform LLC
2 publications, 0.31%
Medknow
2 publications, 0.31%
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.31%
20
40
60
80
100
120
140
160
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
644
Share
Cite this
GOST |
Cite this
GOST Copy
Kellar D., Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches // The Lancet Neurology. 2020. Vol. 19. No. 9. pp. 758-766.
GOST all authors (up to 50) Copy
Kellar D., Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches // The Lancet Neurology. 2020. Vol. 19. No. 9. pp. 758-766.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/S1474-4422(20)30231-3
UR - https://doi.org/10.1016/S1474-4422(20)30231-3
TI - Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches
T2 - The Lancet Neurology
AU - Kellar, Derek
AU - Craft, S.
PY - 2020
DA - 2020/09/01
PB - Elsevier
SP - 758-766
IS - 9
VL - 19
PMID - 32730766
SN - 1474-4422
SN - 1474-4465
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Kellar,
author = {Derek Kellar and S. Craft},
title = {Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches},
journal = {The Lancet Neurology},
year = {2020},
volume = {19},
publisher = {Elsevier},
month = {sep},
url = {https://doi.org/10.1016/S1474-4422(20)30231-3},
number = {9},
pages = {758--766},
doi = {10.1016/S1474-4422(20)30231-3}
}
MLA
Cite this
MLA Copy
Kellar, Derek, and S. Craft. “Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.” The Lancet Neurology, vol. 19, no. 9, Sep. 2020, pp. 758-766. https://doi.org/10.1016/S1474-4422(20)30231-3.